These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 24009294

  • 21. Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade.
    Ferrari P, Marti HP, Pfister M, Frey FJ.
    J Hypertens; 2002 Jan; 20(1):125-30. PubMed ID: 11791035
    [Abstract] [Full Text] [Related]

  • 22. Potassium handling with dual renin-angiotensin system inhibition in diabetic nephropathy.
    Van Buren PN, Adams-Huet B, Nguyen M, Molina C, Toto RD.
    Clin J Am Soc Nephrol; 2014 Feb; 9(2):295-301. PubMed ID: 24408116
    [Abstract] [Full Text] [Related]

  • 23. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control.
    Hunsicker LG.
    J Manag Care Pharm; 2004 Sep; 10(5 Suppl A):S12-7. PubMed ID: 15369420
    [Abstract] [Full Text] [Related]

  • 24. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2005 Jul; 46(1):45-51. PubMed ID: 15983956
    [Abstract] [Full Text] [Related]

  • 25. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
    Morales E, Gutiérrez E, Caro J, Sevillano A, Rojas-Rivera J, Praga M.
    Nefrologia; 2015 Jul; 35(6):554-61. PubMed ID: 26519114
    [Abstract] [Full Text] [Related]

  • 26. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
    Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH.
    Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
    [Abstract] [Full Text] [Related]

  • 27. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B.
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [Abstract] [Full Text] [Related]

  • 28. ACEI and ARB combination therapy in patients with macroalbuminuric diabetic nephropathy and low socioeconomic level: a double-blind randomized clinical trial.
    Titan SM, M Vieira J, Dominguez WV, Barros RT, Zatz R.
    Clin Nephrol; 2011 Oct; 76(4):273-83. PubMed ID: 21955862
    [Abstract] [Full Text] [Related]

  • 29. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ, Song JH, Suh JH, Lee SW, Kim GA.
    Yonsei Med J; 2003 Jun 30; 44(3):463-72. PubMed ID: 12833584
    [Abstract] [Full Text] [Related]

  • 30. Pharmacologic management of diabetic nephropathy.
    Vivian EM, Rubinstein GB.
    Clin Ther; 2002 Nov 30; 24(11):1741-56; discussion 1719. PubMed ID: 12501871
    [Abstract] [Full Text] [Related]

  • 31. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N, Kalaitzidis R, Bakris GL.
    Am J Nephrol; 2009 Nov 30; 30(5):418-24. PubMed ID: 19738369
    [Abstract] [Full Text] [Related]

  • 32. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
    Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN.
    Br J Clin Pharmacol; 2012 Mar 30; 73(3):447-54. PubMed ID: 21950312
    [Abstract] [Full Text] [Related]

  • 33. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy.
    Abe H, Minatoguchi S, Ohashi H, Murata I, Minagawa T, Okuma T, Yokoyama H, Takatsu H, Takaya T, Nagano T, Osumi Y, Kakami M, Tsukamoto T, Tanaka T, Hiei K, Fujiwara H.
    Hypertens Res; 2007 Oct 30; 30(10):929-35. PubMed ID: 18049024
    [Abstract] [Full Text] [Related]

  • 34. Add-on angiotensin receptor blockade with maximized ACE inhibition.
    Agarwal R.
    Kidney Int; 2001 Jun 30; 59(6):2282-9. PubMed ID: 11380832
    [Abstract] [Full Text] [Related]

  • 35. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J, Diabetics Exposed to Telmisartan and Enalapril Study Group.
    N Engl J Med; 2004 Nov 04; 351(19):1952-61. PubMed ID: 15516696
    [Abstract] [Full Text] [Related]

  • 36. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
    Shoda J, Kanno Y, Suzuki H.
    Intern Med; 2006 Nov 04; 45(4):193-8. PubMed ID: 16543688
    [Abstract] [Full Text] [Related]

  • 37. Renal Protective Effects of Combination of Diltiazem and ACEI/ARB on the Progression of Diabetic Nephropathy: Randomized Controlled Trial.
    Krairittichai U, Sarinnapakorn V, Mahannopkul R, Ainwan P.
    J Med Assoc Thai; 2017 Feb 04; 100 Suppl 1():S40-7. PubMed ID: 29927180
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
    Kato S, Maruyama S, Makino H, Wada J, Ogawa D, Uzu T, Araki H, Koya D, Kanasaki K, Oiso Y, Goto M, Nishiyama A, Kobori H, Imai E, Ando M, Matsuo S.
    Clin Exp Nephrol; 2015 Dec 04; 19(6):1098-106. PubMed ID: 25795029
    [Abstract] [Full Text] [Related]

  • 40. Aldosterone antagonists for preventing the progression of chronic kidney disease.
    Navaneethan SD, Nigwekar SU, Sehgal AR, Strippoli GF.
    Cochrane Database Syst Rev; 2009 Jul 08; (3):CD007004. PubMed ID: 19588415
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.